The Rise in Psychedelic Research
We have witnessed an exponential increase in the number of private companies developing proprietary analogues of psychedelic compounds such as psilocybin, DMT and LSD.
While many hope these compounds provide improved safety profiles and higher efficacy, their success is not guaranteed. An alternative route for many of these new chemical entities may be repurposing. If a drug like psilocybin gets approved for the treatment of depression, it may get used off-label, as is currently being done with ketamine. However, real-world data supporting the efficacy of such treatments will be needed before off-label use is permitted.
Ultimately, well-designed clinical trials with larger numbers of participants are needed in psychedelic healthcare. Regulatory agencies require vast troves of data before deciding if such drugs can reach the market. Nonetheless, the use of psychedelic medicines for specific indications may soon become a reality.READ MORE